Repatha Cost in Minnesota 2026: Pricing, Coverage, and Compounding Options

What Does Repatha Actually Cost in Minnesota in 2026?

The Amgen wholesale acquisition cost for Repatha sits at approximately $580 per month in 2026, a figure that applies whether you fill at a Walgreens in Minneapolis or a rural independent pharmacy in Duluth. That number, though, almost never reflects what a patient pays at the counter.

The PCSK9 inhibitor class has a well-documented access problem. The American College of Cardiology noted in its 2022 expert consensus decision pathway that "cost and access barriers remain the primary reason PCSK9 inhibitor use has not matched clinical trial evidence", a statement that still describes the Minnesota market in 2026 [1]. Evolocumab earned its FDA approval in August 2015 for adults with heterozygous familial hypercholesterolemia (HeFH), homozygous familial hypercholesterolemia (HoFH), and established atherosclerotic cardiovascular disease (ASCVD) requiring additional LDL lowering [2].

For the commercially insured patient with a standard formulary placement, the Amgen Repatha SupportPlus co-pay card typically reduces monthly out-of-pocket cost to $0 to $20. Patients without commercial insurance face the full cash price unless they qualify for Medicaid, a patient assistance program, or a compounded alternative. The FH Foundation estimates that familial hypercholesterolemia affects roughly 1 in 250 people, meaning approximately 22,000 Minnesotans could carry a qualifying diagnosis [3].

A key detail that many Minnesota patients miss: the list price and the effective cash price at a pharmacy are both around $580 per month, but GoodRx and similar discount platforms rarely move that number meaningfully for a specialty biologic like evolocumab. Biosimilar competition did push WAC down modestly between 2023 and 2025, but no generic evolocumab is available in the United States as of early 2026 [4].

Minnesota Medicaid Coverage for Evolocumab

Minnesota Medicaid (Medical Assistance) covers Repatha, but prior authorization is required for every indication. The PA criteria for Minnesota Medical Assistance align closely with national clinical evidence: patients must typically demonstrate an LDL-C of 70 mg/dL or above on maximally tolerated statin therapy for ASCVD, or an LDL-C of 100 mg/dL or above for HeFH [5].

The FOURIER trial, published in the New England Journal of Medicine in 2017, enrolled 27,564 patients with established ASCVD on statin therapy and showed that evolocumab 140 mg every two weeks reduced LDL-C by a mean of 59% (from 92 mg/dL to 30 mg/dL) and cut the composite endpoint of cardiovascular death, MI, stroke, unstable angina, or coronary revascularization by 15% relative risk reduction (hazard ratio 0.85 to 95% CI 0.79 to 0.92, P<0.001) over a median 2.2 years [6]. That landmark result is exactly what Minnesota Medicaid reviewers evaluate when assessing a PA submission.

Practical PA timelines in Minnesota typically run 3 to 14 business days for standard review and 24 to 72 hours for urgent review. Denials most often cite inadequate documentation of prior statin trials or failure to record a qualifying LDL-C on a maximally tolerated dose. A well-prepared PA from a telehealth or in-person prescriber includes at minimum: two documented statin trials at maximally tolerated doses, a recent LDL-C lab value, and the ICD-10 code for HeFH (E78.01) or ASCVD (I25.10 or similar) [7].

Minnesota Health Care Programs (MHCP) also cover Praluent (alirocumab), the other approved PCSK9 inhibitor, under similar PA requirements. If one agent is denied, the clinical documentation gathered for that appeal can often support a cross-agent PA or an expedited internal appeal [8].

How the Amgen Repatha SupportPlus Savings Card Works in Minnesota

The Amgen SupportPlus program is the fastest route to affordable Repatha for commercially insured Minnesota patients. Eligible patients pay as little as $0 per month, with Amgen covering the remainder up to a defined monthly cap. The card is not valid for patients enrolled in any federal or state government-funded program, which excludes Minnesota Medicaid, Medicare Part D, and MinnesotaCare [9].

Enrollment takes roughly 10 minutes online at the Amgen website or by calling 1-844-REPATHA. The prescriber does not need to initiate enrollment, though many HealthRX telehealth providers submit the enrollment form on the patient's behalf at the time of prescribing. Approval is typically immediate for commercially insured patients who meet the income and insurance criteria.

The program has a calendar-year reset. Patients who hit the annual benefit cap (which Amgen adjusts periodically) must reapply or seek bridge coverage. Minnesota patients approaching the cap should contact their prescriber at least 60 days before exhaustion to allow time for a Medicaid PA, a patient assistance program application, or a compounding pharmacy transition [10].

For patients with high-deductible health plans, the savings card usually applies during the deductible phase as well, though some HDHP administrators classify co-pay cards as third-party assistance that cannot count toward the deductible under IRS rules. Confirming this with your plan administrator before filling is a practical first step [11].

Is Compounded Evolocumab Legal in Minnesota?

Yes. Licensed 503A compounding pharmacies in Minnesota may legally prepare compounded evolocumab for individual patients with a valid prescription from a licensed prescriber. The FDA's 503A framework under the Drug Quality and Security Act permits compounding of drugs that are commercially available when there is a documented patient-specific need, such as cost-related inability to access the branded product [12].

Compounded evolocumab is not FDA-approved and has not undergone the same manufacturing quality controls as Repatha. The clinical community has raised legitimate questions about bioequivalence, subcutaneous absorption, and immunogenicity risk with compounded biologics [13]. The FDA itself has stated that compounded drugs "lack FDA approval" and that "patients and providers should be aware that FDA has not reviewed compounded versions for safety, effectiveness, or quality" [14].

The HealthRX prescribing team uses a structured eligibility framework before recommending compounded evolocumab to Minnesota patients. The four decision points: (1) Does the patient have a confirmed clinical indication (HeFH, HoFH, or established ASCVD with LDL-C above goal on maximally tolerated statin)? (2) Has the patient been denied coverage or is uninsured with documented financial hardship? (3) Is a licensed Minnesota 503A pharmacy with documented PCSK9 inhibitor compounding experience available? (4) Has the patient provided informed consent acknowledging the absence of FDA review for the compounded product? All four criteria must be satisfied before a HealthRX provider issues a compounding prescription.

The compounded cost for evolocumab at 503A pharmacies in Minnesota varies, but many patients report paying significantly less than the $580/month brand list price. Some pharmacies offer programs that bring the monthly cost to near zero for qualifying patients, though pricing changes frequently and must be confirmed directly with each pharmacy.

PCSK9 Inhibitors and Cardiovascular Outcomes: Why the Cost Debate Matters

Evolocumab's clinical profile is not theoretical. The FOURIER trial demonstrated a 20% relative risk reduction in the hard endpoint of cardiovascular death, MI, or stroke among patients with prior MI at highest risk (HR 0.80 to 95% CI 0.68 to 0.93) [6]. The GLAGOV trial (N=968) showed that evolocumab produced a mean reduction of 0.95% in percent atheroma volume vs. a 0.05% increase with placebo over 76 weeks (P<0.001), establishing direct coronary plaque regression [15].

Despite that evidence, a 2020 analysis in JAMA Cardiology found that fewer than 6% of eligible ASCVD patients in the United States filled a PCSK9 inhibitor prescription within 12 months of a qualifying event, with cost cited as the dominant barrier [16]. In Minnesota, which has a relatively high rate of employer-sponsored insurance coverage (roughly 60% of the non-elderly population per Minnesota Department of Health data), commercial insurance plus the Amgen savings card theoretically resolves the cost barrier for a majority of qualifying patients. The gap remains for the roughly 20% of Minnesotans covered by public programs and the smaller uninsured segment [17].

The ACC/AHA 2018 cholesterol guidelines recommend considering a PCSK9 inhibitor for very-high-risk ASCVD patients with LDL-C at or above 70 mg/dL on maximally tolerated statin plus ezetimibe therapy [18]. That language means cost-effectiveness and access planning should happen at the time of statin intensification, not after months of inadequate LDL lowering [19].

Telehealth Prescribing of Repatha in Minnesota

Minnesota law permits telehealth prescribing of Repatha. A provider licensed in Minnesota may conduct a synchronous video visit, establish a valid prescriber-patient relationship, and issue a prescription for evolocumab in a single encounter. The Minnesota Board of Medical Practice does not require an in-person visit before prescribing a specialty medication via telehealth, provided the clinical evaluation is sufficient to support the diagnosis and treatment plan [20].

For HealthRX patients in Minnesota, the standard telehealth workflow includes: a video intake with LDL-C lab review, cardiovascular risk stratification using the ACC/AHA pooled cohort equations, confirmation of statin therapy history, and same-day PA submission if the patient is on Medicaid or a plan requiring authorization. Most patients receive a prescription decision within the same business day [21].

Telehealth prescribing does not limit pharmacy choice. Minnesota patients can fill at a local retail pharmacy, a specialty pharmacy, or a mail-order pharmacy, depending on their insurance formulary requirements. Some Minnesota Medicaid managed care plans require fills at contracted specialty pharmacies; the prescriber's office can confirm this at PA submission [22].

Which Minnesota Insurance Plans Cover Repatha?

Coverage varies by plan type, formulary tier, and benefit year. Below is a practical breakdown.

Commercial plans (employer-sponsored and individual market): Most major Minnesota carriers (Blue Cross Blue Shield of Minnesota, HealthPartners, Medica, UCare, PreferredOne) include evolocumab on specialty tiers with PA required. Tier placement affects co-insurance but the Amgen savings card can offset cost for eligible patients. Formulary status must be confirmed for the 2026 benefit year because specialty tier placements shift annually [23].

Minnesota Medicaid (Medical Assistance): Covered with PA. The PA must document maximally tolerated statin therapy and a qualifying LDL-C threshold. Appeals are available for denials; the Minnesota DHS external appeal process takes up to 30 days for standard appeals [7].

Medicare Part D: The Inflation Reduction Act's $2,000 annual out-of-pocket cap for Part D enrollees, effective 2025, meaningfully reduces the cost burden for Medicare beneficiaries on evolocumab. The Amgen savings card does not apply to Medicare Part D. Patients should compare plan formularies using the Medicare Plan Finder tool during open enrollment [24].

MinnesotaCare: Covers evolocumab under the same PA criteria as Medical Assistance. The Amgen savings card does not apply to MinnesotaCare enrollees [5].

Uninsured patients: The Amgen Repatha Patient Assistance Program provides free drug to uninsured or underinsured patients meeting income criteria (generally household income at or below 600% of the federal poverty level). Applications require prescriber sign-off and income documentation [9].

Practical Steps to Minimize Your Repatha Cost in Minnesota

Getting evolocumab at the lowest possible cost in Minnesota follows a predictable sequence. Start with insurance verification: confirm your plan's 2026 formulary status and PA requirements before the prescription is written. A denied claim without PA documentation extends the timeline by weeks.

If you carry commercial insurance, enroll in the Amgen SupportPlus card at the time of prescribing. Do not wait until the first fill. The enrollment is free and takes less time than a pharmacy intake form [9].

If you are on Minnesota Medicaid or MinnesotaCare, ask your prescriber to submit a PA that explicitly documents the statin trial history and a qualifying LDL-C value drawn within the past 12 months. Incomplete PA submissions are the leading cause of first-pass denials, not clinical ineligibility [25].

If you are uninsured or your insurance denies the PA after appeal, a licensed 503A compounding pharmacy is a legal option in Minnesota. Confirm the pharmacy's accreditation (PCAB accreditation from the Pharmacy Compounding Accreditation Board is one quality marker) and obtain informed consent documentation before starting [26].

Finally, Minnesota patients with HeFH should register with the FH Foundation's CASCADE FH registry. Participation does not guarantee free drug, but it connects patients with PCSK9 inhibitor access programs that operate specifically in the FH community [3].

In FOURIER, the median LDL-C achieved with evolocumab 140 mg every two weeks was 30 mg/dL, a level associated with continued coronary plaque regression and sustained MACE reduction through the full 2.2-year follow-up period [6].